Current status of quinoxaline and quinoxaline 1,4-di-N-oxides derivatives as potential antiparasitic agents.
Quinoxaline derivatives
antiparasitic agents
quinoxaline 1,4-di-N-oxides
structure-activity relationship
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
19
06
2021
received:
13
03
2021
accepted:
26
06
2021
pubmed:
22
7
2021
medline:
8
1
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
Parasitic diseases are a public health problem, especially in developing countries where millions of people are affected every year. Current treatments have several drawbacks: emerging resistance to the existing drugs, lack of efficacy, and toxic side effects. Therefore, new antiparasitic drugs are urgently needed to treat and control diseases that affect human health, such as malaria, Chagas disease, leishmaniasis, amebiasis, giardiasis schistosomiasis, and filariasis, among others. Quinoxaline is a compound containing a benzene ring and a pyrazine ring. The oxidation of both pyrazine ring nitrogens allows the obtention of quinoxaline 1,4-di-N-oxides (QdNOs) derivatives. By modifying the chemical structure of these compounds, it is possible to obtain a wide variety of biological properties. This review investigated the activity of quinoxaline derivatives and QdNOs against different protozoan parasites and helminths. We also cover the structure-activity relationship (SAR) and summarize the main findings related to their mechanisms of action from published works in recent years. However, further studies are needed to determine specific molecular targets. This review aims to highlight the new development of antiparasitic drugs with better pharmacological profiles than current treatments.
Substances chimiques
Antiparasitic Agents
0
Oxides
0
Pyrazines
0
Quinoxalines
0
Benzene
J64922108F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-699Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
Organisme : Ministerio de Ciencia, Tecnología e Innovación, Colombia
Organisme : Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Abdelfattah, M. S., Kazufumi, T., & Ishibashi, M. (2010). Izumiphenazines A-C: Isolation and structure elucidation of phenazine derivatives from Streptomyces sp. IFM 11204. Journal of Natural Products, 73(12), 1999-2002. https://doi.org/10.1021/np100400t
Abosede, O. O., Vyas, N. A., Singh, S. B., Kumbhar, A. S., Kate, A., Kumbhar, A. A., & Obaleye, J. A. (2016). Copper(ii) mixed-ligand polypyridyl complexes with doxycycline - structures and biological evaluation. Dalton Transactions, 45(7), 3003-3012. https://doi.org/10.1039/c5dt04405g
Aguilera-Venegas, B., Olea-Azar, C., Norambuena, E., Arán, V. J., Mendizábal, F., Lapier, M., Maya, J. D., Kemmerling, U., & López-Muñoz, R. (2011). ESR, electrochemical, molecular modeling and biological evaluation of 4-substituted and 1,4-disubstituted 7-nitroquinoxalin-2-ones as potential anti-Trypanosoma cruzi agents. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 78(3), 1004-1012. https://doi.org/10.1016/j.saa.2010.12.017
Álvarez, G., Aguirre-López, B., Varela, J., Cabrera, M., Merlino, A., López, G. V., Lavaggi, M. L., Porcal, W., Di Maio, R., González, M., Cerecetto, H., Cabrera, N., Pérez-Montfort, R., de Gómez-Puyou, M. T., & Gómez-Puyou, A. (2010). Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity. European Journal of Medicinal Chemistry, 45(12), 5767-5772. https://doi.org/10.1016/j.ejmech.2010.09.034
Bansal, D., Sehgal, R., Chawla, Y., Malla, N., & Mahajan, R. C. (2006). Multidrug resistance in amoebiasis patients. The Indian Journal of Medical Research, 124(2), 189-194.
Baquedano, Y., Alcolea, V., Toro, M. Á., Gutiérrez, K. J., Nguewa, P., Font, M., Moreno, E., Espuelas, S., Jiménez-Ruiz, A., Palop, J. A., Plano, D., & Sanmartín, C. (2016). Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents. Antimicrobial Agents and Chemotherapy, 60(6), 3802-3812. https://doi.org/10.1128/aac.02529-15
Barber, R. S., Braude, R., Hosking, Z. D., & Mitchell, K. G. (1979). Olaquindox as performance-promoting feed additive for growing pigs. Animal Feed Science and Technology, 4(2), 117-123. https://doi.org/10.1016/0377-8401(79)90036-1
Barbosa-Cabrera, E., Moo-Puc, R., Monge, A., Paz-González, A. D., Bocanegra-García, V., & Rivera, G. (2020). In vitro and in vivo evaluation of quinoxaline 1,4-di-n-oxide against giardia lamblia. Letters in Drug Design & Discovery, 17(4), 428-433. https://doi.org/10.2174/1570180816666190618115854
Barea, C., Pabón, A., Castillo, D., Zimic, M., Quiliano, M., Galiano, S., Pérez-Silanes, S., Monge, A., Deharo, E., & Aldana, I. (2011). New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities. Bioorganic & Medicinal Chemistry Letters, 21(15), 4498-4502. https://doi.org/10.1016/j.bmcl.2011.05.125
Barea, C., Pabón, A., Galiano, S., Pérez-Silanes, S., Gonzalez, G., Deyssard, C., Monge, A., Deharo, E., & Aldana, I. (2012). Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido) quinoxaline 1,4-dioxide derivatives. Molecules, 17(8), 9451-9461. https://doi.org/10.3390/molecules17089451
Barea, C., Pabón, A., Pérez-Silanes, S., Galiano, S., Gonzalez, G., Monge, A., Deharo, E., & Aldana, I. (2013). New amide derivatives of quinoxaline 1,4-di-N-oxide with leishmanicidal and antiplasmodial activities. Molecules, 18(4), 4718-4727. https://doi.org/10.3390/molecules18044718
Bekhit, A. A., El-Agroudy, E., Helmy, A., Ibrahim, T. M., Shavandi, A., & Bekhit, A.- E.-D.- A. (2018). Leishmania treatment and prevention: Natural and synthesized drugs. European Journal of Medicinal Chemistry, 160, 229-244. https://doi.org/10.1016/j.ejmech.2018.10.022
Benitez, D., Cabrera, M., Hernández, P., Boiani, L., Lavaggi, M. L., Di Maio, R., & Monge, A. (2011). 3-Trifluoromethylquinoxaline N, N’-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies. Journal of Medicinal Chemistry, 54(10), 3624-3636. https://doi.org/10.1021/jm2002469
Benítez, D., Casanova, G., Cabrera, G., Galanti, N., Cerecetto, H., & González, M. (2014). Initial studies on mechanism of action and cell death of active N-oxide-containing heterocycles in Trypanosoma cruzi epimastigotes in vitro. Parasitology, 141(5), 682-696. https://doi.org/10.1017/s003118201300200x
Bhoj, P., Ingle, R., Goswami, K., Jena, L., & Wadher, S. (2018). Apoptotic impact on Brugia malayi by sulphonamido-quinoxaline: Search for a novel therapeutic rationale. Parasitology Research, 117(5), 1559-1572. https://doi.org/10.1007/s00436-018-5834-6
Bonilla-Ramírez, L., Galiano, S., Quiliano, M., Aldana, I., & Pabón, A. (2019). Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species. Malaria Journal, 18(1). https://doi.org/10.1186/s12936-019-2825-8
Bonilla-Ramirez, L., Rios, A., Quiliano, M., Ramirez-Calderon, G., Beltrán-Hortelano, I., Franetich, J. F., Corcuera, L., Bordessoulles, M., Vettorazzi, A., López de Cerain, A., Aldana, I., Mazier, D., Pabón, A., & Galiano, S. (2018). Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies. European Journal of Medicinal Chemistry, 158, 68-81. https://doi.org/10.1016/j.ejmech.2018.08.063
Brandonisio, O., Panaro, M. A., Sisto, M., Acquafredda, A., Fumarola, L., Leogrande, D., & Mitolo, V. (2001). Nitric oxide production by Leishmania-infected macrophages and modulation by cytokines and prostaglandins. Parassitologia, 43, 1-6.
Brizuela, M., Huang, H. M., Smith, C., Burgio, G., Foote, S. J., & McMorran, B. J. (2014). Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine. PLoS One, 9(4), e92411. https://doi.org/10.1371/journal.pone.0092411
Brož, J., Sevcik, B., & Hebky, T. (2009). Growth promoting activity of cyadox in piglet rearing. Zeitschrift Für Tierphysiologie, Tierernahrung Und Futtermittelkunde, 41(1-6), 237-242. https://doi.org/10.1111/j.1439-0396.1978.tb00587.x
Camps, M., Rückle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., & Rommel, C. (2005). Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Medicine, 11(9), 936-943. https://doi.org/10.1038/nm1284
Cavazzuti, A., Paglietti, G., Hunter, W. N., Gamarro, F., Piras, S., Loriga, M., Allecca, S., Corona, P., McLuskey, K., Tulloch, L., Gibellini, F., Ferrari, S., & Costi, M. P. (2008). Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proceedings of the National Academy of Sciences of the USA, 105(5), 1448-1453. https://doi.org/10.1073/pnas.0704384105
Chacón-Vargas, K. F., Andrade-Ochoa, S., Nogueda-Torres, B., Juárez-Ramírez, D. C., Lara-Ramírez, E. E., Mondragón-Flores, R., Monge, A., Rivera, G., & Sánchez-Torres, L. E. (2018). Isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives induce regulated necrosis-like cell death on Leishmania (Leishmania) mexicana. Parasitology Research, 117(1), 45-58. https://doi.org/10.1007/s00436-017-5635-3
Chacón-Vargas, K., Nogueda-Torres, B., Sánchez-Torres, L., Suarez-Contreras, E., Villalobos-Rocha, J., Torres-Martinez, Y., Lara-Ramirez, E., Fiorani, G., Krauth-Siegel, R., Bolognesi, M., Monge, A., & Rivera, G. (2017). Trypanocidal activity of quinoxaline 1,4 Di-N-oxide derivatives as trypanothione reductase inhibitors. Molecules, 22(2), 220. https://doi.org/10.3390/molecules22020220
Cheng, G., Sa, W., Cao, C., Guo, L., Hao, H., Liu, Z., Wang, X. U., & Yuan, Z. (2016). Quinoxaline 1,4-di-N-oxides: Biological activities and mechanisms of actions. Frontiers in Pharmacology, 7, 64. https://doi.org/10.3389/fphar.2016.00064
Cobo, F. (2016). Determinants of parasite drug resistance in human lymphatic filariasis. Revista Espanola De Quimioterapia: Publicacion Oficial De La Sociedad Espanola De Quimioterapia, 29(6), 288-295.
Cogo, J., Cantizani, J., Cotillo, I., Sangi, D. P., Corrêa, A. G., Ueda-Nakamura, T., Filho, B. P. D., Martín, J. J., & Nakamura, C. V. (2018). Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents. Bioorganic & Medicinal Chemistry, 26(14), 4065-4072. https://doi.org/10.1016/j.bmc.2018.06.033
Cogo, J., Kaplum, V., Sangi, D. P., Ueda-Nakamura, T., Corrêa, A. G., & Nakamura, C. V. (2015). Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 90, 107-123. https://doi.org/10.1016/j.ejmech.2014.11.018
Corbett, Y., D’Alessandro, S., Parapini, S., Scaccabarozzi, D., Kalantari, P., Zava, S., Giavarini, F., Caruso, D., Colombo, I., Egan, T. J., & Basilico, N. (2018). Interplay between Plasmodium falciparum haemozoin and L-arginine: Implication for nitric oxide production. Malaria Journal, 17(1), 456. https://doi.org/10.1186/s12936-018-2602-0
Cummings, H. E., Barbi, J., Reville, P., Oghumu, S., Zorko, N., Sarkar, A., Keiser, T. L., Lu, B., Ruckle, T., Varikuti, S., Lezama-Davila, C., Wewers, M. D., Whitacre, C., Radzioch, D., Rommel, C., Seveau, S., & Satoskar, A. R. (2012). Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proceedings of the National Academy of Sciences of the USA, 109(4), 1251-1256. https://doi.org/10.1073/pnas.1110339109
D’Arcy, M. (2019). Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biology International, 43(6), 582-592. https://doi.org/10.1002/cbin.11137
De Cian, A., Grellier, P., Mouray, E., Depoix, D., Bertrand, H., Monchaud, D., & Alberti, P. (2008). Plasmodium telomeric sequences: Structure, stability and quadruplex targeting by small compounds. ChemBioChem, 9(16), 2730-2739. https://doi.org/10.1002/cbic.200800330
de Oliveira, J. K., Ueda-Nakamura, T., Corrêa, A. G., Petrilli, R., Lopez, R. F. V., Nakamura, C. V., & Auzely-Velty, R. (2020). Liposome-based nanocarrier loaded with a new quinoxaline derivative for the treatment of cutaneous leishmaniasis. Materials Science and Engineering: C, 110, 110720. https://doi.org/10.1016/j.msec.2020.110720.
Desroches, J., Kieffer, C., Primas, N., Hutter, S., Gellis, A., El-Kashef, H., Rathelot, P., Verhaeghe, P., Azas, N., & Vanelle, P. (2017). Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold. European Journal of Medicinal Chemistry, 125, 68-86. https://doi.org/10.1016/j.ejmech.2016.09.029
Drurey, C., Coakley, G., & Maizels, R. M. (2020). Extracellular vesicles: New targets for vaccines against helminth parasites. International Journal for Parasitology, 50(9), 623-633. https://doi.org/10.1016/j.ijpara.2020.04.011
Duque-Montaño, B. E., Gómez-Caro, L. C., Sanchez-Sanchez, M., Monge, A., Hernández-Baltazar, E., Rivera, G., & Torres-Angeles, O. (2013). Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica. Bioorganic & Medicinal Chemistry, 21(15), 4550-4558. https://doi.org/10.1016/j.bmc.2013.05.036
El Hajj, R., Bou Youness, H., Lachaud, L., Bastien, P., Masquefa, C., Bonnet, P.-A., El Hajj, H., & Khalifeh, I. (2018). EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. PLoS Neglected Tropical Diseases, 12(11), e0006854. https://doi.org/10.1371/journal.pntd.0006854
Espinosa, A., Socha, A. M., Ryke, E., & Rowley, D. C. (2012). Antiamoebic properties of the actinomycete metabolites echinomycin A and tirandamycin A. Parasitology Research, 111(6), 2473-2477. https://doi.org/10.1007/s00436-012-3019-2
Estevez, Y., Quiliano, M., Burguete, A., Cabanillas, B., Zimic, M., Málaga, E., Verástegui, M., Pérez-Silanes, S., Aldana, I., Monge, A., Castillo, D., & Deharo, E. (2011). Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives. Experimental Parasitology, 127(4), 745-751. https://doi.org/10.1016/j.exppara.2011.01.009
Ferraro, F., Merlino, A., Gil, J., Cerecetto, H., Corvo, I., & Cabrera, M. (2019). Cathepsin L Inhibitors with Activity against the Liver Fluke Identified from a Focus Library of Quinoxaline 1,4-di-N-Oxide Derivatives. Molecules, 24(13), 2348. https://doi.org/10.3390/molecules24132348
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., & Gilbert, I. H. (2017). Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nature Reviews. Microbiology, 15(4), 217-231. https://doi.org/10.1038/nrmicro.2016.193
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B. (1985). Echinomycin: The first bifunctional intercalating agent in clinical trials. Investigational New Drugs, 3(4), 403-410. https://doi.org/10.1007/bf00170766
Gabay, M., Cabrera, M., Maio, R. D., Paez, J. A., Campillo, N., Lavaggi, M. L., & González, M. (2014). Mutagenicity of N-oxide containing heterocycles and related compounds: Experimental and theoretical studies. Current Topics in Medicinal Chemistry, 14(11), 1374-1387. https://doi.org/10.2174/1568026614666140506123235
Ghosh, A. S., Dutta, S., & Raha, S. (2010). Hydrogen peroxide-induced apoptosis-like cell death in Entamoeba histolytica. Parasitology International, 59(2), 166-172. https://doi.org/10.1016/j.parint.2010.01.001
Gil, A., Pabón, A., Galiano, S., Burguete, A., Pérez-Silanes, S., Deharo, E., Monge, A., & Aldana, I. (2014). Synthesis, biological evaluation and structure-activity relationships of new quinoxaline derivatives as anti-Plasmodium falciparum agents. Molecules, 19(2), 2166-2180. https://doi.org/10.3390/molecules19022166
Guillon, J., Cohen, A., Gueddouda, N. M., Das, R. N., Moreau, S., Ronga, L., & Sonnet, P. (2017). Design, synthesis and antimalarial activity of novel bis{N-[(pyrrolo[1,2-a]quinoxalin-4-yl)benzyl]-3-aminopropyl}amine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 32(1), 547-563. https://doi.org/10.1080/14756366.2016.1268608
Guillon, J., Grellier, P., Labaied, M., Sonnet, P., Léger, J.-M., Déprez-Poulain, R., & Jarry, C. (2004). Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines. Journal of Medicinal Chemistry, 47(8), 1997-2009. https://doi.org/10.1021/jm0310840
Haque, R. (2007). Human intestinal parasites. Journal of Health, Population and Nutrition, 25(4), 387-391. PMC2754014.
Haraldsen, J. D., Liu, G. U., Botting, C. H., Walton, J. G. A., Storm, J., Phalen, T. J., Kwok, L. Y., Soldati-Favre, D., Heintz, N. H., Müller, S., Westwood, N. J., & Ward, G. E. (2009). Identification of Conoidin a as a covalent inhibitor of peroxiredoxin ii. Organic & Biomolecular Chemistry, 7(15), 3040-3048. https://doi.org/10.1039/b901735f
Hawkins, P. T., & Stephens, L. R. (2015). PI3K signalling in inflammation. Biochimica Et Biophysica Acta, 1851(6), 882-897. https://doi.org/10.1016/j.bbalip.2014.12.006
Hayase, H., Watanabe, N., Lim, C., Nogawa, T., Komatsuya, K., Kita, K., & Osada, H. (2015). Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity. Bioscience, Biotechnology, and Biochemistry, 79(4), 633-635. https://doi.org/10.1080/09168451.2014.987205
Hotez, P. J., Aksoy, S., Brindley, P. J., & Kamhawi, S. (2020). What constitutes a neglected tropical disease? PLoS Neglected Tropical Diseases, 14(1), e0008001. https://doi.org/10.1371/journal.pntd.0008001
Hayase, H., Watanabe, N., Lim, C. L., Nogawa, T., Komatsuya, K., Kita, K., & Osada, H. (2015). Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity. Bioscience, Biotechnology, and Biochemistry, 79(4), 633-635.
Hu, Y., Wang, K., & MacMillan, J. B. (2013). Hunanamycin A, an antibiotic from a marine-derived Bacillus hunanensis. Organic Letters, 15(2), 390-393. https://doi.org/10.1021/ol303376c
Ibáñez-Escribano, A., Reviriego, F., Nogal-Ruiz, J. J., Meneses-Marcel, A., Gómez-Barrio, A., Escario, J., & Arán, V. J. (2015). Synthesis and in vitro and in vivo biological evaluation of substituted nitroquinoxalin-2-ones and 2,3-diones as novel trichomonacidal agents. European Journal of Medicinal Chemistry, 94, 276-283. https://doi.org/10.1016/j.ejmech.2015.03.002
Ingram-Sieber, K., Cowan, N., Panic, G., Vargas, M., Mansour, N. R., Bickle, Q. D., Wells, T. N. C., Spangenberg, T., & Keiser, J. (2014). Orally active antischistosomal early leads identified from the open access malaria box. PLoS Neglected Tropical Diseases, 8(1), e2610. https://doi.org/10.1371/journal.pntd.0002610
Jong, R. M., Tebeje, S. K., Meerstein-Kessel, L., Tadesse, F. G., Jore, M. M., Stone, W., & Bousema, T. (2020). Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunological Reviews, 293(1), 190-215. https://doi.org/10.1111/imr.12828
Kaczanowski, S., Sajid, M., & Reece, S. E. (2011). Evolution of apoptosis-like programmed cell death in unicellular protozoan parasites. Parasites & Vectors, 4(1), 44. https://doi.org/10.1186/1756-3305-4-44
KalantarMotamedi, Y., Eastman, R. T., Guha, R., & Bender, A. (2018). A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria. Malaria Journal, 17(1), https://doi.org/10.1186/s12936-018-2294-5
Kaplum, V., Cogo, J., Sangi, D. P., Ueda-Nakamura, T., Corrêa, A. G., & Nakamura, C. V. (2016). In VitroandIn VivoActivities of 2,3-diarylsubstituted quinoxaline derivatives against Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 60(6), 3433-3444. https://doi.org/10.1128/aac.02582-15
Kelley, J. M., Elliott, T. P., Beddoe, T., Anderson, G., Skuce, P., & Spithill, T. W. (2016). Current threat of triclabendazole resistance in Fasciola hepatica. Trends in Parasitology, 32(6), 458-469. https://doi.org/10.1016/j.pt.2016.03.002
Kleim, J. P., Bender, R., Billhardt, U. M., Meichsner, C., Riess, G., Rösner, M., Winkler, I., & Paessens, A. (1993). Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrobial Agents and Chemotherapy, 37(8), 1659-1664. https://doi.org/10.1128/aac.37.8.1659
Lizarazo-Jaimes, E. H., Reis, P. G., Bezerra, F. M., Rodrigues, B. L., Monte-Neto, R. L., Melo, M. N., Frézard, F., & Demicheli, C. (2014). Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites. Journal of Inorganic Biochemistry, 132, 30-36. https://doi.org/10.1016/j.jinorgbio.2013.12.001
Lu, J., & Holmgren, A. (2014). The thioredoxin antioxidant system. Free Radical Biology & Medicine, 66, 75-87. https://doi.org/10.1016/j.freeradbiomed.2013.07.036
Marcu, L., & Olver, I. (2006). Tirapazamine: From bench to clinical trials. Current Clinical Pharmacology, 1(1), 71-79. https://doi.org/10.2174/157488406775268192
Morin, C., Besset, T., Moutet, J.-C., Fayolle, M., Brückner, M., Limosin, D., Becker, K., & Davioud-Charvet, E. (2008). The aza-analogues of 1,4-naphthoquinones are potent substrates and inhibitors of plasmodial thioredoxin and glutathione reductases and of human erythrocyte glutathione reductase. Organic & Biomolecular Chemistry, 6(15), 2731-2742. https://doi.org/10.1039/b802649c
Nguyen, J. B., Pool, C. D., Wong, C. Y. B., Treger, R. S., Williams, D. L., Cappello, M., Lea, W. A., Simeonov, A., Vermeire, J. J., & Modis, Y. (2013). Peroxiredoxin-1 from the human hookworm Ancylostoma ceylanicum forms a stable oxidized decamer and is covalently inhibited by conoidin A. Chemistry & Biology, 20(8), 991-1001. https://doi.org/10.1016/j.chembiol.2013.06.011
Nogueira, N. P., Saraiva, F. M. S., Oliveira, M. P., Mendonça, A. P. M., Inacio, J. D. F., Almeida-Amaral, E. E., Menna-Barreto, R. F., Laranja, G. A. T., Torres, E. J. L., Oliveira, M. F., & Paes, M. C. (2017). Heme modulates Trypanosoma cruzi bioenergetics inducing mitochondrial ROS production. Free Radical Biology & Medicine, 108, 183-191. https://doi.org/10.1016/j.freeradbiomed.2017.03.027
Olsen, A. (2007). Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Transactions of the Royal Society of Tropical Medicine & Hygiene, 101(8), 747-758. https://doi.org/10.1016/j.trstmh.2007.03.006
Orjuela, L. I., Morales, J. A., Ahumada, M. L., Rios, J. F., González, J. J., Yañez, J., Rosales, A., Cabarcas, D. M., Venegas, J., Yasnot, M. F., & Quiñones, M. L. (2018). Insecticide resistance and its intensity in populations of malaria vectors in Colombia. BioMed Research International, 2018, 1-12. https://doi.org/10.1155/2018/9163543
Otto, T. D., Gilabert, A., Crellen, T., Böhme, U., Arnathau, C., Sanders, M., Oyola, S. O., Okouga, A. P., Boundenga, L., Willaume, E., Ngoubangoye, B., Moukodoum, N. D., Paupy, C., Durand, P., Rougeron, V., Ollomo, B., Renaud, F., Newbold, C., Berriman, M., & Prugnolle, F. (2018). Genomes of all known members of a Plasmodium subgenus reveal paths to virulent human malaria. Nature Microbiology, 3(6), 687-697. https://doi.org/10.1038/s41564-018-0162-2
Palos, I., Moo-Puc, R., Vique-Sánchez, J. L., Benítez-Cardoza, C. G., Monge, A., Villalobos-Rocha, J. C., & Rivera, G. (2021). Esters of quinoxaline-7-carboxylate-1,4-di-N-oxide as Trichomonas vaginalis triosephosphate isomerase inhibitors. Acta Pharmaceutica, 71(3), 485-495. https://doi.org/10.2478/acph-2021-0032
Patel, N. B., Patel, J. N., Purohit, A. C., Patel, V. M., Rajani, D. P., Moo-Puc, R., Lopez-Cedillo, J. C., Nogueda-Torres, B., & Rivera, G. (2017). In vitro and in vivo assessment of newer quinoxaline-oxadiazole hybrids as antimicrobial and antiprotozoal agents. International Journal of Antimicrobial Agents, 50(3), 413-418. https://doi.org/10.1016/j.ijantimicag.2017.04.016
Pérez-Silanes, S., Torres, E., Arbillaga, L., Varela, J., Cerecetto, H., González, M., Azqueta, A., & Moreno-Viguri, E. (2016). Synthesis and biological evaluation of quinoxaline di- N -oxide derivatives with in vitro trypanocidal activity. Bioorganic & Medicinal Chemistry Letters, 26(3), 903-906. https://doi.org/10.1016/j.bmcl.2015.12.070
Planer, J. D., Hulverson, M. A., Arif, J. A., Ranade, R. M., Don, R., & Buckner, F. S. (2014). Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 8(7), e2977. https://doi.org/10.1371/journal.pntd.0002977
Prast-Nielsen, S., Huang, H.-H., & Williams, D. L. (2011). Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases. Biochimica Et Biophysica Acta. General Subjects, 1810(12), 1262-1271. https://doi.org/10.1016/j.bbagen.2011.06.024
Rodrigues, J. H. D. S., Ueda-Nakamura, T., Corrêa, A. G., Sangi, D. P., & Nakamura, C. V. (2014). A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi. PLoS One, 9(1), e85706. https://doi.org/10.1371/journal.pone.0085706
Romeiro, N. C., Aguirre, G., Hernández, P., González, M., Cerecetto, H., Aldana, I., Pérez-Silanes, S., Monge, A., Barreiro, E. J., & Lima, L. M. (2009). Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic & Medicinal Chemistry, 17(2), 641-652. https://doi.org/10.1016/j.bmc.2008.11.065
Ronga, L., Del Favero, M., Cohen, A., Soum, C., Le Pape, P., Savrimoutou, S., Pinaud, N., Mullié, C., Daulouede, S., Vincendeau, P., Farvacques, N., Agnamey, P., Pagniez, F., Hutter, S., Azas, N., Sonnet, P., & Guillon, J. (2014). Design, synthesis and biological evaluation of novel 4-alkapolyenylpyrrolo[1,2-a]quinoxalines as antileishmanial agents - Part III. European Journal of Medicinal Chemistry, 81, 378-393. https://doi.org/10.1016/j.ejmech.2014.05.037
Ross, F., Hernández, P., Porcal, W., López, G. V., Cerecetto, H., González, M., Basika, T., Carmona, C., Fló, M., Maggioli, G., Bonilla, M., Gladyshev, V. N., Boiani, M., & Salinas, G. (2012). Identification of thioredoxin glutathione reductase inhibitors that kill cestode and trematode parasites. PLoS One, 7(4), e35033. https://doi.org/10.1371/journal.pone.0035033
Schumann, J. A., & Plasner, S. (2018). Trichomoniasis.
Soto-Sánchez, J., Caro-Gómez, L. A., Paz-González, A. D., Marchat, L. A., Rivera, G., Moo-Puc, R., Arias, D. G., & Ramírez-Moreno, E. (2020). Biological activity of esters of quinoxaline-7-carboxylate 1,4-di-N-oxide against E. histolytica and their analysis as potential thioredoxin reductase inhibitors. Parasitology Research, 119(2), 695-711. https://doi.org/10.1007/s00436-019-06580-8
Steinerová, N., Lipavská, H., Stajner, K., Čáslavská, J., Blumauerová, M., Cudlín, J., & Vank, Z. (1987). Production of quinomycin A inStreptomyces lasaliensis. Folia Microbiologica, 32(1), 1-5. https://doi.org/10.1007/bf02877251
Stephens, L., Ellson, C., & Hawkins, P. (2002). Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Current Opinion in Cell Biology, 14(2), 203-213. https://doi.org/10.1016/s0955-0674(02)00311-3
Tariq, S., Somakala, K., & Amir, M. (2018). Quinoxaline: An insight into the recent pharmacological advances. European Journal of Medicinal Chemistry, 143, 542-557. https://doi.org/10.1016/j.ejmech.2017.11.064
Thrasher, G. W., Shively, J. E., Askelson, C. E., Babcock, W. E., & Chalquest, R. R. (1969). Effects of feeding carbadox upon the growth and performance of young pigs. Journal of Animal Science, 28(2), 208-215. https://doi.org/10.2527/jas1969.282208x
Torres, E., Moreno-Viguri, E., Galiano, S., Devarapally, G., Crawford, P. W., Azqueta, A., Arbillaga, L., Varela, J., Birriel, E., Di Maio, R., Cerecetto, H., González, M., Aldana, I., Monge, A., & Pérez-Silanes, S. (2013). Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. European Journal of Medicinal Chemistry, 66, 324-334. https://doi.org/10.1016/j.ejmech.2013.04.065
Vale, N., Gouveia, M. J., Rinaldi, G., Brindley, P. J., Gärtner, F., & Correia da Costa, J. M. (2017). Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance. Antimicrobial Agents & Chemotherapy, 61(5), https://doi.org/10.1128/aac.02582-16
Villalba, J. D., Gómez, C., Medel, O., Sánchez, V., Carrero, J. C., Shibayama, M., & Ishiwara, D. G. P. (2007). Programmed cell death in Entamoeba histolytica induced by the aminoglycoside G418. Microbiology, 153(Pt 11), 3852-3863. https://doi.org/10.1099/mic.0.2007/008599-0
Villalobos-Rocha, J. C., Sánchez-Torres, L., Nogueda-Torres, B., Segura-Cabrera, A., García-Pérez, C. A., Bocanegra-García, V., Palos, I., Monge, A., & Rivera, G. (2014). Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives. Parasitology Research, 113(6), 2027-2035. https://doi.org/10.1007/s00436-014-3850-8
World Health Organization (WHO). (2021). Retrieved from https://www.who.int/health-topics/#S
Zarranz, B., Jaso, A., Aldana, I., Monge, A., Maurel, S., Deharo, E., Jullian, V., & Sauvain, M. (2005). Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. Arzneimittel-Forschung, 55(12), 754-761. https://doi.org/10.1055/s-0031-1296926